Found 0 matching trials
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females PHASE3 The purpose of this study is to evaluate the immunogenicity and the safety ...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study PHASE3 This extension study is conducted to assess the efficacy of the GSK 580299 ...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older PHASE3 This is a multicentre study in which women were planned to receive either t...
Show More Location
GSK Investigational Site
Learn More & Join Trial
The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine PHASE4 The purpose of this study is to evaluate the immunogenicity and safety of R...
Show More Location
Yuecheng Center for Disease Control and Prevention
Learn More & Join Trial
Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years PHASE3 Human papillomavirus infection has clearly been recognized as the cause of ...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women PHASE3 The study will be extended for subjects who received all three doses of vac...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine PHASE2 Infection with human papillomavirus (HPV) has been clearly established as t...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females PHASE2 Infection with human papillomavirus (HPV) has been clearly established as t...
Show More Location
GSK Investigational Site
Learn More & Join Trial
The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study PHASE3 This extension study is designed to assess the safety of GSK Biological's H...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age. PHASE3 Cervical cancer is the second most common cancer among women worldwide. App...
Show More Location
GSK Investigational Site
Learn More & Join Trial